News for MMEDF Stock

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics MindMed To Commence Trading on Nasdaq MindMed Announces the Publication of New Data on Personalized MDMA Dosing MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board MindMed Announces Inclusion in FTSE Russell Indexes MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company MindMed's LSD Neutralizer Study Begins MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor MindMed Confirms No Material Change MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines